Coloplast (COLO) Investor presentation summary

Financial performance and guidance

• Q1 2025/26 organic revenue grew 6%, with reported growth flat due to currency and divestment impacts; EBIT before special items decreased 3% to DKK 1,850 million, with a margin of 26%.

• Free cash flow was DKK 1,821 million, with a FCF-to-sales ratio of 26%, supported by lower net financial items.

• FY 2025/26 guidance remains at around 7% organic growth and 7% EBIT growth in constant currencies, with ROIC expected to improve by 1 percentage point.

• Reported growth in DKK is expected at 4%, with a 3%-point negative impact from currencies and a small negative impact from the skin care divestment.

• Tax rate is expected to remain around 22% during the strategic period, benefiting from recent IP transfers.

Business segment performance

• Ostomy Care grew 4% organically, impacted by negative growth in China and a high baseline in the US; growth expected to pick up later in the year.

• Continence Care delivered 7% organic growth, led by the Luja™ catheter platform for both male and female users.

• Voice & Respiratory Care grew 8%, driven by Laryngectomy and broad-based geographic growth.

• Wound & Tissue Repair grew 5%, with Kerecis delivering 10% organic growth but facing sales disruption from Medicare reimbursement changes.

• Interventional Urology grew 8%, led by strong US Men's Health performance and recovery in Kidney & Bladder Health.

Strategic priorities and Impact4

• Impact4 strategy focuses on four pillars: innovative customer offerings, efficiency gains, technology adoption, and cultivating a winning, sustainable company.

• Ambition for 7-8% organic revenue growth (5-year CAGR) and ROIC above 20% by FY 2029/30.

• Dynamic resource allocation is fueling high-potential areas such as US Chronic Care, Kerecis, and Intibia commercialization.

• All business segments are expected to contribute to growth, with Chronic Care as the largest driver.